2
|
Rognoni T, Fernández-Matarrubia M, Martinez-González MÁ, Salas-Salvadó J, Corella D, Castañer O, Martínez JA, Alonso-Gómez ÁM, Gómez-Gracia E, Vioque J, Romaguera D, López-Miranda J, Estruch R, Tinahones FJ, Santos-Lozano JM, Serra-Majem L, Cano Ibañez N, Tur JA, Micó Pérez R, Pintó X, Delgado-Rodríguez M, Ortiz Ramos M, Vidal J, Vázquez C, Daimiel L, Ros E, Goñi-Ruiz N, Babio N, Sorlí JV, Schröder H, García-Rios A, Compañ-Gabucio L, Warnberg J, Zulet MÁ, Chaplin A, Sacanella E, Bouzalmate-Hajjaj A, Tojal-Sierra L, Damas-Fuentes M, Vázquez Z, Gómez-Martínez C, Saiz C, Malcampo M, Ortiz-Morales AM, Martínez-Avilés V, García-Gavilan J, Abete I, Fitó M, Toledo E. Two-Year Changes in Physical Activity and Concurrent Changes in Cognitive Function in a Cohort of Adults with Metabolic Syndrome. J Alzheimers Dis 2023; 95:887-899. [PMID: 37661880 DOI: 10.3233/jad-230105] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/05/2023]
Abstract
BACKGROUND It has been proposed that physical activity (PA) could prevent cognitive decline. OBJECTIVE To evaluate the association between changes in PA and changes in cognitive function in a cohort of adults with metabolic syndrome. METHODS Longitudinal observational study including 5,500 adults (mean age 65 years, SD = 5; women = 49.3% ) with metabolic syndrome. Participants underwent physical activity measurements and cognitive evaluation at baseline and at two-years of follow-up. PA was quantified using the Minnesota questionnaire-shortened version. Cognitive function was evaluated using a battery of tests: Mini-Mental Test Examination, Clock Drawing Test, Trail Making Test A and B, Verbal Fluency Test, and Digit Span. The primary outcome was two-year change in cognition, measured through the Global Composite Score (GCS) of all neuropsychological tests. Multivariable-adjusted linear regression models were fitted with baseline PA and their changes as the main exposures and changes in cognitive function as the outcome. RESULTS No significant association was found between PA levels (or their changes) in the GCS of cognitive function. A greater increase in PA levels was associated with a more favorable two-year change in the Trail Making Test A (Q4 versus Q1: b = - 2.24s, 95% CI -4.36 to -0.12s; p-trend = 0.020). No significant association was found for other neuropsychological test. CONCLUSION Our results do not support an association between increases in PA and the evolution of the global cognitive function at two-year in an intervention trial which included PA promotion in one of its two randomized arms, but they suggested a possible beneficial effect of PA on attentional function in older adults.
Collapse
Affiliation(s)
- Teresa Rognoni
- Department of Neurology, Clínica Universidad de Navarra, Madrid, Spain
| | | | - Miguel Ángel Martinez-González
- Department of Preventive Medicine and Public Health, University of Navarra, Pamplona, Spain
- IdiSNA, Navarra Institute for Health Research, Pamplona, Spain
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain
- Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA
| | - Jordi Salas-Salvadó
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain
- Universitat Rovira i Vigili, Department de Bioquímica i Biotecnología, Unitat de Nutrició Humana, Reus, Spain
- Institut d'Investigació Sanitària Pere i Virgili (IISPV), Hospital San Joan de Reus, Reus, Spain
| | - Dolores Corella
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain
- Department of Preventive Medicine, University of Valencia, Valencia, Spain
| | - Olga Castañer
- Cardiovascular Risk and Nutrition, Hospital del Mar Research Institute (IMIM), Barcelona, Spain
- Centro de Investigación Biomédica en Red Epidemiología y Salud Pública (CIBERESP), Institute of Health Carlos III, Madrid, Spain
| | - J Alfredo Martínez
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain
- Department of Nutrition, Food Sciences, and Physiology, Center for Nutrition Research, University of Navarra, Pamplona, Spain
- Nutritional Control of the Epigenome Group, Precision Nutrition and Obesity Program, IMDEA Food, CEI UAM + CSIC, Madrid, Spain
| | - Ángel M Alonso-Gómez
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain
- Bioaraba Health Research Institute, Cardiovascular, Respiratory and Metabolic Area; Osakidetza Basque Health Service, Araba University Hospital; University of the Basque Country UPV/EHU, Vitoria-Gasteiz, Spain
| | - Enrique Gómez-Gracia
- Department of Preventive Medicine and Public Health, Instituto de Investigación Biomédica de Málaga-IBIMA, School of Medicine, University of Málaga, Málaga, Spain
| | - Jesús Vioque
- Centro de Investigación Biomédica en Red Epidemiología y Salud Pública (CIBERESP), Institute of Health Carlos III, Madrid, Spain
- Instituto de Investigación Sanitaria y Biomédica de Alicante, Universidad Miguel Hernández (ISABIAL-UMH).Alicante, Spain
| | - Dora Romaguera
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain
- Research Group on Nutritional Epidemiology & Cardiovascular Physiopathology (NUTRECOR), HealthResearch Institute of the Balearic Islands (IdISBa), Palma de Mallorca, Spain
| | - José López-Miranda
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain
- Department of Internal Medicine, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Córdoba, Córdoba, Spain
| | - Ramón Estruch
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain
- Department of Internal Medicine, Institut de I'nvestigacions Biomèdiques August Pi Sunyer (IDIBAPS), Hospital Clinic, University of Barcelona, Barcelona, Spain
| | - Francisco J Tinahones
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain
- Department of Endocrinology, Virgen de la Victoria Hospital, Instituto de Investigación Biomédica de Málaga (IBIMA). University of Málaga, Málaga, Spain
| | - José Manuel Santos-Lozano
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain
- Department of Family Medicine, Research Unit, Distrito Sanitario Atención Primaria Sevilla, Sevilla, Spain
| | - Lluis Serra-Majem
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain
- Research Institute of Biomedical and Health Sciences (IUIBS), University of Las Palmas de Gran Canaria and Centro Hospitalario Universitario Insular Materno Infantil (CHUIMI), Canarian Health Service, Las Palmas de Gran Canaria, Spain
| | - Naomi Cano Ibañez
- Centro de Investigación Biomédica en Red Epidemiología y Salud Pública (CIBERESP), Institute of Health Carlos III, Madrid, Spain
- Department of Preventive Medicine and Public Health, University of Granada, Granada, Spain
- Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, Spain
| | - Josep A Tur
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain
- Research Group on Community Nutrition and Oxidative Stress, University of Balearic Islands-IUNICS, Palma de Mallorca, Spain
| | - Rafael Micó Pérez
- Centro de Investigación Biomédica en Red Epidemiología y Salud Pública (CIBERESP), Institute of Health Carlos III, Madrid, Spain
- Institute of Biomedicine (IBIOMED), University of León, León, Spain
| | - Xavier Pintó
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain
- Lipids and Vascular Risk Unit, Internal Medicine, Hospital Universitario de Bellvitge, Hospitalet de Llobregat, Spain
| | - Miguel Delgado-Rodríguez
- Centro de Investigación Biomédica en Red Epidemiología y Salud Pública (CIBERESP), Institute of Health Carlos III, Madrid, Spain
- Division of Preventive Medicine, Faculty of Medicine, University of Jaén, Jaén, Spain
| | - María Ortiz Ramos
- Department of Endocrinology and Nutrition, Instituto de Investigación Sanitaria Hospital Clínico San Carlos (IdISSC), Madrid, Spain
| | - Josep Vidal
- Lipid Clinic, Department of Endocrinology and Nutrition, Institut d'Investigacions Biomèdiques August Pi Sunyer (IDIBAPS), Hospital Clínic, Barcelona, Spain
- CIBER Diabetes y Enfermedades Metabólicas (CIBERDEM), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
| | - Clotilde Vázquez
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain
- Department of Endocrinology and Nutrition, Hospital Fundación Jiménez Díaz, Instituto de Investigaciones Biomédicas IISFJD, University Autónoma, Madrid, Spain
| | - Lidia Daimiel
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain
- Nutritional Control of the Epigenome Group, Precision Nutrition and Obesity Program, IMDEA Food, CEI UAM + CSIC, Madrid, Spain
- Departamento de Ciencias Farmacéuticas y de la Salud, Faculty de Farmacia, Universidad San Pablo-CEU, CEU Universities, Boadilla del Monte, Spain
| | - Emilio Ros
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain
- Lipid Clinic, Department of Endocrinology and Nutrition, Institut d'Investigacions Biomèdiques August Pi Sunyer (IDIBAPS), Hospital Clínic, Barcelona, Spain
| | - Nuria Goñi-Ruiz
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain
- Servicios de Atención Primaria, Navarra Regional Health Service (Osasunbidea), Pamplona, Spain
| | - Nancy Babio
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain
- Universitat Rovira i Vigili, Department de Bioquímica i Biotecnología, Unitat de Nutrició Humana, Reus, Spain
- Institut d'Investigació Sanitària Pere i Virgili (IISPV), Hospital San Joan de Reus, Reus, Spain
| | - José V Sorlí
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain
- Department of Preventive Medicine, University of Valencia, Valencia, Spain
| | - Helmut Schröder
- Cardiovascular Risk and Nutrition, Hospital del Mar Research Institute (IMIM), Barcelona, Spain
- Centro de Investigación Biomédica en Red Epidemiología y Salud Pública (CIBERESP), Institute of Health Carlos III, Madrid, Spain
| | - Antonio García-Rios
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain
- Department of Internal Medicine, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Córdoba, Córdoba, Spain
| | - Laura Compañ-Gabucio
- Instituto de Investigación Sanitaria y Biomédica de Alicante, Universidad Miguel Hernández (ISABIAL-UMH).Alicante, Spain
| | - Julia Warnberg
- Department of Nursing, School of Health Sciences University of Malaga, Spain
- Instituto de Investigación Biomédica de Málaga-IBIMA, Málaga, Spain
| | - M Ángeles Zulet
- IdiSNA, Navarra Institute for Health Research, Pamplona, Spain
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain
- Department of Nutrition, Food Sciences, and Physiology, Center for Nutrition Research, University of Navarra, Pamplona, Spain
| | - Alice Chaplin
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain
- Research Group on Nutritional Epidemiology & Cardiovascular Physiopathology (NUTRECOR), HealthResearch Institute of the Balearic Islands (IdISBa), Palma de Mallorca, Spain
| | - Emilio Sacanella
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain
- Department of Internal Medicine, Institut de I'nvestigacions Biomèdiques August Pi Sunyer (IDIBAPS), Hospital Clinic, University of Barcelona, Barcelona, Spain
| | - Amira Bouzalmate-Hajjaj
- Centro de Investigación Biomédica en Red Epidemiología y Salud Pública (CIBERESP), Institute of Health Carlos III, Madrid, Spain
- Department of Preventive Medicine and Public Health, University of Granada, Granada, Spain
| | - Lucas Tojal-Sierra
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain
- Bioaraba Health Research Institute, Cardiovascular, Respiratory and Metabolic Area; Osakidetza Basque Health Service, Araba University Hospital; University of the Basque Country UPV/EHU, Vitoria-Gasteiz, Spain
| | - Miguel Damas-Fuentes
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain
- Department of Endocrinology, Virgen de la Victoria Hospital, Instituto de Investigación Biomédica de Málaga (IBIMA). University of Málaga, Málaga, Spain
| | - Zenaida Vázquez
- Department of Preventive Medicine and Public Health, University of Navarra, Pamplona, Spain
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain
| | - Carlos Gómez-Martínez
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain
- Universitat Rovira i Vigili, Department de Bioquímica i Biotecnología, Unitat de Nutrició Humana, Reus, Spain
- Institut d'Investigació Sanitària Pere i Virgili (IISPV), Hospital San Joan de Reus, Reus, Spain
| | - Carmen Saiz
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain
- Department of Preventive Medicine, University of Valencia, Valencia, Spain
| | - Mireia Malcampo
- Cardiovascular Risk and Nutrition, Hospital del Mar Research Institute (IMIM), Barcelona, Spain
| | - Ana M Ortiz-Morales
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain
- Department of Internal Medicine, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Córdoba, Córdoba, Spain
| | | | - Jesús García-Gavilan
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain
- Universitat Rovira i Vigili, Department de Bioquímica i Biotecnología, Unitat de Nutrició Humana, Reus, Spain
- Institut d'Investigació Sanitària Pere i Virgili (IISPV), Hospital San Joan de Reus, Reus, Spain
| | - Itziar Abete
- IdiSNA, Navarra Institute for Health Research, Pamplona, Spain
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain
- Department of Nutrition, Food Sciences, and Physiology, Center for Nutrition Research, University of Navarra, Pamplona, Spain
| | - Montserrat Fitó
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain
- Cardiovascular Risk and Nutrition, Hospital del Mar Research Institute (IMIM), Barcelona, Spain
| | - Estefanía Toledo
- Department of Preventive Medicine and Public Health, University of Navarra, Pamplona, Spain
- IdiSNA, Navarra Institute for Health Research, Pamplona, Spain
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain
| |
Collapse
|
5
|
Prat A, Martínez de Dueñas E, Galván P, Garcia S, Burgués O, Paré L, Antolín S, Martinello R, Blancas I, Adamo B, Guerrero Á, Muñoz M, Nuciforo P, Vidal M, Pérez RM, Chacón JI, Caballero R, Gascón P, Carrasco E, Rojo F, Perou CM, Cortés J, Adamo V, Albanell J, Lluch A. Abstract P6-05-02: Intrinsic subtype and gene expression changes between primary and metastatic breast cancer. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p6-05-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: A better understanding of the biological changes occurring during metastatic progression of breast cancer is needed to identify new biomarkers, targets and novel treatment strategies. Here, we compared the intrinsic subtype and the expression of a gene panel across a large dataset of paired primary and metastatic tissues.
Methods: Expression profiling of 105 breast cancer-related genes was performed on 254 (127 pairs) formalin-fixed paraffin-embedded tumor tissues using the nCounter platform. Tumor samples were obtained from 3 independent sources (ConvertHER trial [BCRT 2014] and two in-house datasets). Tumors were classified into each intrinsic subtype using the research-based PAM50 classifier (Parker et al. J Clin Oncol 2009). Chi-square tests were performed to determine the differences in the distribution of variables. Paired two-class Significance of Microarrays (SAM) was performed to determine the genes differentially expressed between paired primary and metastatic tissues. In vitro stable transfection of FGFR4-GFP was performed on Luminal B MCF7 cell line. RNA was purified on control vs. transfected cell lines. 7-AAD cell viability was performed following estrogen deprivation for 6 days.
Results: Subtype distribution in primary vs. metastatic disease was 39.0% vs. 26.8% for Luminal A (p=0.012), 26.0% vs. 35.0% for Luminal B (p=0.322), 11.4% vs. 20.3% for HER2-enriched (p=0.115) and 10.6% vs. 13.0% for Basal-like tumors (p=0.843). The rate of subtype conversion was 7.7% in Basal-like, 23.1% in HER2-enriched, 30.0% in Luminal B and 54.3% in Luminal A disease. The majority of subtype conversions in Luminal A disease were to Luminal B (72.0%) and HER2-enriched (24.0%). Overall, 13.2% of primary Luminal A/B tumors progressed to a HER2-E subtype despite 70% of them being clinically HER2-negative. In a paired analysis using all samples, 10- and 12- genes were found up- and down- regulated in metastatic tissues (False Discovery Rate [FDR] <5%). The up-regulated gene list in metastatic disease was composed of FGFR4 (top gene) and proliferation genes (CDC6, CCNB1, CEP55). The down-regulated gene list in metastatic disease was enriched for luminal-related genes (ESR1, PGR, NAT1 and MAPT). A similar paired analysis within Luminal A, Luminal B, HER2-enriched and Basal-like disease revealed 22, 8, 7 and 0 differentially expressed genes (FDR<5%), respectively. Finally, MCF7 cell line transfected with FGFR4 showed a relative increase in the HER2-enriched profile compared with transfected control. In vitro, MCF7-FGFR4 cells showed estrogen independent growth compared to transfected controls.
Conclusions: Metastatic tissues are relatively more proliferative and less luminal compared to primary tumors. This is especially relevant in primary Luminal A disease. In contrast, metastatic tissues from Basal-like primary disease remain largely unchanged. In luminal disease, a significant increase in the HER2-enriched profile is observed in metastatic disease despite most tumors being clinically HER2-negative. A potential driver of the HER2-enriched profile and estrogen independence in clinically HER2-negative metastatic tissues might be FGFR4.
Citation Format: Prat A, Martínez de Dueñas E, Galván P, Garcia S, Burgués O, Paré L, Antolín S, Martinello R, Blancas I, Adamo B, Guerrero Á, Muñoz M, Nuciforo P, Vidal M, Pérez RM, Chacón JI, Caballero R, Gascón P, Carrasco E, Rojo F, Perou CM, Cortés J, Adamo V, Albanell J, Lluch A. Intrinsic subtype and gene expression changes between primary and metastatic breast cancer. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P6-05-02.
Collapse
Affiliation(s)
- A Prat
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic -- IDIBAPS, Barcelona, Spain; Hospital Provincial de Castellón, Castellón, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Clínico San Cecilio de Granada, Granada, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Universitario Quirón de Madrid, Madrid, Spain; Hospital Virgen de la Salud, Toledo, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Fundación Jiménez Díaz, Madrid, Spain; University of North Carolina, Chapel Hill, NC; University of Messina, Messina, Italy; Hospital del Mar, Barcelona, Spain
| | - E Martínez de Dueñas
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic -- IDIBAPS, Barcelona, Spain; Hospital Provincial de Castellón, Castellón, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Clínico San Cecilio de Granada, Granada, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Universitario Quirón de Madrid, Madrid, Spain; Hospital Virgen de la Salud, Toledo, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Fundación Jiménez Díaz, Madrid, Spain; University of North Carolina, Chapel Hill, NC; University of Messina, Messina, Italy; Hospital del Mar, Barcelona, Spain
| | - P Galván
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic -- IDIBAPS, Barcelona, Spain; Hospital Provincial de Castellón, Castellón, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Clínico San Cecilio de Granada, Granada, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Universitario Quirón de Madrid, Madrid, Spain; Hospital Virgen de la Salud, Toledo, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Fundación Jiménez Díaz, Madrid, Spain; University of North Carolina, Chapel Hill, NC; University of Messina, Messina, Italy; Hospital del Mar, Barcelona, Spain
| | - S Garcia
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic -- IDIBAPS, Barcelona, Spain; Hospital Provincial de Castellón, Castellón, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Clínico San Cecilio de Granada, Granada, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Universitario Quirón de Madrid, Madrid, Spain; Hospital Virgen de la Salud, Toledo, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Fundación Jiménez Díaz, Madrid, Spain; University of North Carolina, Chapel Hill, NC; University of Messina, Messina, Italy; Hospital del Mar, Barcelona, Spain
| | - O Burgués
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic -- IDIBAPS, Barcelona, Spain; Hospital Provincial de Castellón, Castellón, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Clínico San Cecilio de Granada, Granada, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Universitario Quirón de Madrid, Madrid, Spain; Hospital Virgen de la Salud, Toledo, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Fundación Jiménez Díaz, Madrid, Spain; University of North Carolina, Chapel Hill, NC; University of Messina, Messina, Italy; Hospital del Mar, Barcelona, Spain
| | - L Paré
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic -- IDIBAPS, Barcelona, Spain; Hospital Provincial de Castellón, Castellón, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Clínico San Cecilio de Granada, Granada, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Universitario Quirón de Madrid, Madrid, Spain; Hospital Virgen de la Salud, Toledo, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Fundación Jiménez Díaz, Madrid, Spain; University of North Carolina, Chapel Hill, NC; University of Messina, Messina, Italy; Hospital del Mar, Barcelona, Spain
| | - S Antolín
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic -- IDIBAPS, Barcelona, Spain; Hospital Provincial de Castellón, Castellón, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Clínico San Cecilio de Granada, Granada, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Universitario Quirón de Madrid, Madrid, Spain; Hospital Virgen de la Salud, Toledo, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Fundación Jiménez Díaz, Madrid, Spain; University of North Carolina, Chapel Hill, NC; University of Messina, Messina, Italy; Hospital del Mar, Barcelona, Spain
| | - R Martinello
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic -- IDIBAPS, Barcelona, Spain; Hospital Provincial de Castellón, Castellón, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Clínico San Cecilio de Granada, Granada, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Universitario Quirón de Madrid, Madrid, Spain; Hospital Virgen de la Salud, Toledo, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Fundación Jiménez Díaz, Madrid, Spain; University of North Carolina, Chapel Hill, NC; University of Messina, Messina, Italy; Hospital del Mar, Barcelona, Spain
| | - I Blancas
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic -- IDIBAPS, Barcelona, Spain; Hospital Provincial de Castellón, Castellón, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Clínico San Cecilio de Granada, Granada, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Universitario Quirón de Madrid, Madrid, Spain; Hospital Virgen de la Salud, Toledo, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Fundación Jiménez Díaz, Madrid, Spain; University of North Carolina, Chapel Hill, NC; University of Messina, Messina, Italy; Hospital del Mar, Barcelona, Spain
| | - B Adamo
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic -- IDIBAPS, Barcelona, Spain; Hospital Provincial de Castellón, Castellón, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Clínico San Cecilio de Granada, Granada, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Universitario Quirón de Madrid, Madrid, Spain; Hospital Virgen de la Salud, Toledo, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Fundación Jiménez Díaz, Madrid, Spain; University of North Carolina, Chapel Hill, NC; University of Messina, Messina, Italy; Hospital del Mar, Barcelona, Spain
| | - Á Guerrero
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic -- IDIBAPS, Barcelona, Spain; Hospital Provincial de Castellón, Castellón, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Clínico San Cecilio de Granada, Granada, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Universitario Quirón de Madrid, Madrid, Spain; Hospital Virgen de la Salud, Toledo, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Fundación Jiménez Díaz, Madrid, Spain; University of North Carolina, Chapel Hill, NC; University of Messina, Messina, Italy; Hospital del Mar, Barcelona, Spain
| | - M Muñoz
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic -- IDIBAPS, Barcelona, Spain; Hospital Provincial de Castellón, Castellón, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Clínico San Cecilio de Granada, Granada, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Universitario Quirón de Madrid, Madrid, Spain; Hospital Virgen de la Salud, Toledo, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Fundación Jiménez Díaz, Madrid, Spain; University of North Carolina, Chapel Hill, NC; University of Messina, Messina, Italy; Hospital del Mar, Barcelona, Spain
| | - P Nuciforo
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic -- IDIBAPS, Barcelona, Spain; Hospital Provincial de Castellón, Castellón, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Clínico San Cecilio de Granada, Granada, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Universitario Quirón de Madrid, Madrid, Spain; Hospital Virgen de la Salud, Toledo, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Fundación Jiménez Díaz, Madrid, Spain; University of North Carolina, Chapel Hill, NC; University of Messina, Messina, Italy; Hospital del Mar, Barcelona, Spain
| | - M Vidal
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic -- IDIBAPS, Barcelona, Spain; Hospital Provincial de Castellón, Castellón, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Clínico San Cecilio de Granada, Granada, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Universitario Quirón de Madrid, Madrid, Spain; Hospital Virgen de la Salud, Toledo, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Fundación Jiménez Díaz, Madrid, Spain; University of North Carolina, Chapel Hill, NC; University of Messina, Messina, Italy; Hospital del Mar, Barcelona, Spain
| | - RM Pérez
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic -- IDIBAPS, Barcelona, Spain; Hospital Provincial de Castellón, Castellón, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Clínico San Cecilio de Granada, Granada, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Universitario Quirón de Madrid, Madrid, Spain; Hospital Virgen de la Salud, Toledo, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Fundación Jiménez Díaz, Madrid, Spain; University of North Carolina, Chapel Hill, NC; University of Messina, Messina, Italy; Hospital del Mar, Barcelona, Spain
| | - JI Chacón
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic -- IDIBAPS, Barcelona, Spain; Hospital Provincial de Castellón, Castellón, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Clínico San Cecilio de Granada, Granada, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Universitario Quirón de Madrid, Madrid, Spain; Hospital Virgen de la Salud, Toledo, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Fundación Jiménez Díaz, Madrid, Spain; University of North Carolina, Chapel Hill, NC; University of Messina, Messina, Italy; Hospital del Mar, Barcelona, Spain
| | - R Caballero
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic -- IDIBAPS, Barcelona, Spain; Hospital Provincial de Castellón, Castellón, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Clínico San Cecilio de Granada, Granada, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Universitario Quirón de Madrid, Madrid, Spain; Hospital Virgen de la Salud, Toledo, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Fundación Jiménez Díaz, Madrid, Spain; University of North Carolina, Chapel Hill, NC; University of Messina, Messina, Italy; Hospital del Mar, Barcelona, Spain
| | - P Gascón
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic -- IDIBAPS, Barcelona, Spain; Hospital Provincial de Castellón, Castellón, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Clínico San Cecilio de Granada, Granada, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Universitario Quirón de Madrid, Madrid, Spain; Hospital Virgen de la Salud, Toledo, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Fundación Jiménez Díaz, Madrid, Spain; University of North Carolina, Chapel Hill, NC; University of Messina, Messina, Italy; Hospital del Mar, Barcelona, Spain
| | - E Carrasco
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic -- IDIBAPS, Barcelona, Spain; Hospital Provincial de Castellón, Castellón, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Clínico San Cecilio de Granada, Granada, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Universitario Quirón de Madrid, Madrid, Spain; Hospital Virgen de la Salud, Toledo, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Fundación Jiménez Díaz, Madrid, Spain; University of North Carolina, Chapel Hill, NC; University of Messina, Messina, Italy; Hospital del Mar, Barcelona, Spain
| | - F Rojo
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic -- IDIBAPS, Barcelona, Spain; Hospital Provincial de Castellón, Castellón, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Clínico San Cecilio de Granada, Granada, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Universitario Quirón de Madrid, Madrid, Spain; Hospital Virgen de la Salud, Toledo, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Fundación Jiménez Díaz, Madrid, Spain; University of North Carolina, Chapel Hill, NC; University of Messina, Messina, Italy; Hospital del Mar, Barcelona, Spain
| | - CM Perou
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic -- IDIBAPS, Barcelona, Spain; Hospital Provincial de Castellón, Castellón, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Clínico San Cecilio de Granada, Granada, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Universitario Quirón de Madrid, Madrid, Spain; Hospital Virgen de la Salud, Toledo, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Fundación Jiménez Díaz, Madrid, Spain; University of North Carolina, Chapel Hill, NC; University of Messina, Messina, Italy; Hospital del Mar, Barcelona, Spain
| | - J Cortés
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic -- IDIBAPS, Barcelona, Spain; Hospital Provincial de Castellón, Castellón, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Clínico San Cecilio de Granada, Granada, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Universitario Quirón de Madrid, Madrid, Spain; Hospital Virgen de la Salud, Toledo, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Fundación Jiménez Díaz, Madrid, Spain; University of North Carolina, Chapel Hill, NC; University of Messina, Messina, Italy; Hospital del Mar, Barcelona, Spain
| | - V Adamo
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic -- IDIBAPS, Barcelona, Spain; Hospital Provincial de Castellón, Castellón, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Clínico San Cecilio de Granada, Granada, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Universitario Quirón de Madrid, Madrid, Spain; Hospital Virgen de la Salud, Toledo, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Fundación Jiménez Díaz, Madrid, Spain; University of North Carolina, Chapel Hill, NC; University of Messina, Messina, Italy; Hospital del Mar, Barcelona, Spain
| | - J Albanell
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic -- IDIBAPS, Barcelona, Spain; Hospital Provincial de Castellón, Castellón, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Clínico San Cecilio de Granada, Granada, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Universitario Quirón de Madrid, Madrid, Spain; Hospital Virgen de la Salud, Toledo, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Fundación Jiménez Díaz, Madrid, Spain; University of North Carolina, Chapel Hill, NC; University of Messina, Messina, Italy; Hospital del Mar, Barcelona, Spain
| | - A Lluch
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic -- IDIBAPS, Barcelona, Spain; Hospital Provincial de Castellón, Castellón, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Clínico San Cecilio de Granada, Granada, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Universitario Quirón de Madrid, Madrid, Spain; Hospital Virgen de la Salud, Toledo, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Fundación Jiménez Díaz, Madrid, Spain; University of North Carolina, Chapel Hill, NC; University of Messina, Messina, Italy; Hospital del Mar, Barcelona, Spain
| |
Collapse
|